People with relapsing-remitting multiple sclerosis who are treated with the anti-CD20 drug rituximab show a higher risk of developing inflammatory bowel disease, researchers report. Both outlets describe the association as coming from a population-based study that compares rituximab with other disease-modifying treatments.
Medical Xpress says the study is the first large, population-based analysis in this area and notes that inflammatory bowel disease—especially Crohn’s disease—appears more common among rituximab users, while the absolute risk is still low. MedPage Today similarly reports an increased IBD risk versus other MS therapies. Together, the coverage emphasizes the comparative risk signal and that, despite the relative increase, overall event rates remain limited, without detailing any specific absolute numbers in the provided summaries.
